Italy’s Recordati Industria Chimica & Farmaceutica SPA reported OTC sales up by 0.3% to €178m ($195m) in the first half of 2024, as lower demand for cold and flu products held back growth.
Recordati Posts Rise In OTC Sales Despite Weak Cold & Flu Season
OTC sales edged up at Italy's Recordati in the first half of 2024 as higher demand for GI products and supplements offset a weaker cold & flu season.
